BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating

- Advertisement -

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BeiGene (BGNE) stock cleared that benchmark Thursday, with a jump from 77 to 82 Thursday.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock’s price performance over the trailing 52 weeks matches up against the rest of the market.

Decades of market research reveals that the best-performing stocks often have an RS Rating north of 80 as they begin their biggest climbs.

See How IBD Helps You Make More Money In Stocks

Is BeiGene Stock A Buy?

BeiGene stock broke out earlier, but has fallen back below the prior 207.37 entry from a cup without handle. In the case where a stock breaks out then falls 7% or more below the entry price, it’s considered a failed breakout. If that happens, it’s best to wait for a new base to form. Also keep in mind that the most recent pattern is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one.

The Chinese-based biotech company posted 0% earnings growth in its most recent report. Revenue rose 88%.

BeiGene stock holds the No. 163 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab ADR (GMAB) and Harmony Biosciences (HRMY) are also among the group’s highest-rated stocks. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Read More: BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating

- Advertisement -

Notify of
Inline Feedbacks
View all comments